The role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemia

Expert Opinion on Investigational Drugs

Volumn 21, Issue 7, 2012, Pages 1009-1017

  Smolej, Lukáš ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

Bulky lymphadenopathy; Chronic lymphocytic leukemia; Dexamethasone; Fludarabine; Methylprednisolone; Ofatumumab; P53; Refractory disease

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CHLORAMBUCIL; CIPROFLOXACIN; CORTICOTROPIN; CORTISONE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUCONAZOLE; FLUDARABINE; GLUCOCORTICOID RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 90; IMMUNOGLOBULIN; ITRACONAZOLE; METHYLPREDNISOLONE; OFATUMUMAB; PREDNISOLONE; PROTEIN P53; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; BONE MARROW SUPPRESSION; BRADYCARDIA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CATABOLISM; CHRONIC LYMPHATIC LEUKEMIA; CONFUSION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SUBSTITUTION; DUODENUM CANCER; FATIGUE; FLUID RETENTION; GENE DELETION; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; INSOMNIA; LYMPHADENOPATHY; MEDICAL SOCIETY; MEDLINE; META ANALYSIS (TOPIC); METABOLIC ALKALOSIS; MONOTHERAPY; MOOD DISORDER; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; ONCOGENE C MYC; OSTEOPOROSIS; PNEUMONIA; REFRACTORY PERIOD; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SLEEP DISORDER; STOMACH CANCER; THROMBOCYTOPENIA; THRUSH; WEIGHT GAIN;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENES, P53; GLUCOCORTICOIDS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MUTATION; TREATMENT OUTCOME;

EID: 84862287101     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.690393     Document Type: Review

References (69)

1. Dores GM, Anderson WF, Curtis RE, et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol 2007;139:809-19 (Pubitemid 350115721)
2. Dreger P. Allotransplantation for chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2009;602-9
3. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376(9747):1164-74
4. Tsimberidou AM, Keating MJ. Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer 2009;115:2824-36
5. Keating MJ, O'Brien S, Kontoyiannis D, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002;43:1755-62 (Pubitemid 34874007)
6. Keating MJ. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554-61 (Pubitemid 34534522)
7. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:1749-55
8. Lowenberg M, Verhaar AP, van den Brink GR, Hommes DW. Glucocorticoid signaling: a nongenomic mechanism for T-cell immunosuppression. Trends Mol Med 2007;13:158-63 (Pubitemid 46498830)
9. Turner JD, Alt SR, Cao L, et al. Transcriptional control of the glucocorticoid receptor: cpG islands, epigenetics and more. Biochem Pharmacol 2010;80:1860-8
10. Zhou J, Cidlowski JA. The human glucocorticoid receptor: one gene, multiple proteins and diverse responses. Steroids 2005;70:407-17 (Pubitemid 40616039)
11. Harmon JM, Elsasser MS, Eisen LP, et al. Glucocorticoid receptor expression in receptorless mutants isolated from the human leukemic cell line CEM-C7. Mol Endocrinol 1989;3:734-43 (Pubitemid 19108954)
12. Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980;284:555-6 (Pubitemid 10070336)
13. Buttgereit F, Burmester GR, Brand MD. Therapeutically targeting lymphocyte energy metabolism by high-dose glucocorticoids. Biochem Pharmacol 2000;59:597-603. (Pubitemid 30085440)
14. McColl A, Michlewska S, Dransfield I, Rossi AG. Effects of glucocorticoids on apoptosis and clearance of apoptotic cells. Sci World J 2007;7:1165-81 (Pubitemid 47327835)
15. Alnemri ES, Maksymowych AB, Robertson NM, Litwack G. Characterization and purification of a functional rat glucocorticoid receptor overexpressed in a baculovirus system. J Biol Chem 1991;266:3925-36 (Pubitemid 21909298)
16. Rhee K, Bresnahan W, Hirai A, et al. c-Myc and cyclin D3 (CcnD3) genes are independent targets for glucocorticoid inhibition of lymphoid cell proliferation. Cancer Res 1995;55:4188-95
17. Caron-Leslie LA, Cidlowski JA. Similar actions of glucocorticoids and calcium on the regulation of apoptosis in S49 cells. Mol Endocrinol 1991;5:1169-79
18. Adcock IM, Barnes PJ. Molecular mechanisms of corticosteroid resistance. Chest 2008;134:394-401
19. Distelhorst CW. Recent insights into the mechanism of glucocorticosteroidinduced apoptosis. Cell Death Differ 2002;9:6-19 (Pubitemid 34071989)
20. McColl KS, He H, Zhong H, et al. Apoptosis induction by the glucocorticoid hormone dexamethasone and the calcium-ATPase inhibitor thapsigargin involves Bc1-2 regulated caspase activation. Mol Cell Endocrinol 1998;139:229-38 (Pubitemid 28340074)
21. Laane E, Panaretakis T, Pokrovskaja K, et al. Dexamethasone-induced apoptosis in acute lymphoblastic leukemia involves differential regulation of Bcl-2 family members. Haematologica 2007;92:1460-9 (Pubitemid 350144120)
22. Laane E, Tamm KP, Buentke E, et al. Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy. Cell Death Differ 2009;16:1018-29
23. Grander D, Kharaziha P, Laane E, et al. Autophagy as the main means of cytotoxicity by glucocorticoids in hematological malignancies. Autophagy 2009;5:1198-200
24. Johnston JB, Daeninck P, Verburg L, et al. P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia. Leuk Lymphoma 1997;26:435-49. (Pubitemid 27477770)
25. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-16 (Pubitemid 32064784)
26. Zenz T, Mertens D, Dohner H, Stilgenbauer S. Importance of genetics in chronic lymphocytic leukemia. Blood Rev 2011;25:131-7
27. Zenz T, Mohr J, Edelmann J, et al. Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway. Leuk Lymphoma 2009;50:510-13
28. Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2010;2010:481-8
29. Moghadam-Kia S, Werth VP. Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol 2010;49:239-48
30. Franchimont D. Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies. Ann NY Acad Sci 2004;1024:124-37 (Pubitemid 38879597)
31. Klein NC, Go CH, Cunha BA. Infections associated with steroid use. Infect Dis Clin North Am 2001;15:423-32.viii (Pubitemid 32606908)
32. Pearson OH, Eliel LP, et al. Adrenocorticotropic hormone-and cortisone-induced regression of lymphoid tumors in man; a preliminary report. Cancer 1949;2:943-5
33. Ezdinli EZ, Stutzman L, Aungst CW, Firat D. Corticosteroid therapy for lymphomas and chronic lymphocytic leukemia. Cancer 1969;23:900-9
34. Burningham RA, Restrepo A, Pugh RP, et al. Weekly high-dosage glucocorticosteroid treatment of lymphocytic leukemias and lymphomas. N Engl J Med 1964;270:1160-6
35. Han T, Ezdinli EZ, Shimaoka K, Desai DV. Chlorambucil vs. combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia. Cancer 1973;31:502-8
36. Sawitsky A, Rai KR, Glidewell O, Silver RT. Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood 1977;50:1049-59 (Pubitemid 8245208)
37. Montserrat E, Alcala A, Parody R, et al. Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone. Cancer 1985;56:2369-75 (Pubitemid 16202426)
38. Liepman M, Votaw ML. The treatment of chronic lymphocytic leukemia with COP chemotherapy. Cancer 1978;41:1664-9 (Pubitemid 8335371)
39. Leporrier M. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001;98:2319-25
40. Catovsky D, Fooks J, Richards S. The UK Medical Research Council CLL trials 1 and 2. Nouv Rev Fr Hematol 1988;30:423-7 (Pubitemid 19011873)
41. Keating MJ, O'Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998;92:1165-71 (Pubitemid 28369029)
42. O'Brien S, Kantarjian H, Beran M, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993;82:1695-700 (Pubitemid 23278758)
43. Robak T, Blonski JZ, Kasznicki M, et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000;96:2723-9
44. Oken MM, Lee S, Kay NE, et al. Pentostatin, chlorambucil and prednisone therapy for B-chronic lymphocytic leukemia: a phase I/II study by the Eastern Cooperative Oncology Group study E1488. Leuk Lymphoma 2004;45:79-84 (Pubitemid 38181397)
45. Laurencet F, Ballabeni P, Rufener B, et al. The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas. Acta Haematol 2007;117:40-7 (Pubitemid 46012423)
46. CLL Trialists' Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J Natl Cancer Inst 1999;91:861-8.
47. Hamblin TJ. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol 2006;33:230-9
48. Zent CS, Kay NE. Autoimmune complications in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol 2010;23:47-59
49. Schwartz CL, Thompson EB, Gelber RD, et al. Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia. J Clin Oncol 2001;19:1040-6 (Pubitemid 32176279)
50. Yetgin S, Tuncer MA, Cetin M, et al. Benefit of high-dose methylprednisolone in comparison with conventional-dose prednisolone during remission induction therapy in childhood acute lymphoblastic leukemia for long-term follow-up. Leukemia 2003;17:328-33 (Pubitemid 36266909)
51. Veerman AJ, Kamps WA, van den Berg H, et al. Childhood Oncology Group. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol 2009;10:957-66
52. Buttgereit F, da Silva JA, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 2002;61:718-22. (Pubitemid 34787710)
53. Bosanquet AG, McCann SR, Crotty GM, et al. Methylprednisolone in advanced chronic lymphocytic leukaemia: rationale for, and effectiveness of treatment suggested by DiSC assay. Acta Haematol 1995;93:73-9.
54. Thornton PD, Hamblin M, Treleaven JG, et al. High dose methyl prednisolone in refractory chronic lymphocytic leukaemia. Leuk Lymphoma 1999;34:167-70 (Pubitemid 29248672)
55. Thornton PD, Matutes E, Bosanquet AG, et al. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol 2003;82:759-65. (Pubitemid 38008843)
56. Xu W, Miao KR, Hong M, et al. High-dose methylprednisolone can induce remissions in patients with fludarabine-refractory chronic lymphocytic leukaemia. Eur J Cancer 2010;46:2145-9
57. Rose AL, Smith BE, Maloney DG. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood 2002;100:1765-73 (Pubitemid 34925155)
58. Bowen DA, Call TG, Jenkins GD, et al. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma 2007;48:2412-17 (Pubitemid 350253473)
59. Dungarwalla M, Evans SO, Riley U, et al. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica 2008;93(3):475-6 (Pubitemid 351398657)
60. Castro JE, Sandoval-Sus JD, Bole J, et al. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 2008;22:2048-53
61. Pileckyte R, Jurgutis M, Valceckiene V, et al. Dose-dense high-dos methylprednisolone and rituximab in the treatment of relapsed orrefractory high-risk chronic lymphocytic leukemia. Leuk Lymphoma 2011;52:1055-65
62. Hardman JG, Limbird LE. editors. Goodman and Gilman's the pharmacological basis of therapeutics. 9th edition. Mc Graw-Hill; New York: 1998
63. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984;24310:1353-6 (Pubitemid 14149087)
64. Quinn JP, Mohamedbhai S, Chipperfield K, et al. Efficacy of rituximab in combination with steroids in refractory chronic lymphocytic leukemia. Leuk Lymphoma 2008;49:1995-8.
65. Castro JE, Barajas-Gamboa JS, Melo-Cardenas J, et al. Ofatumumab and high-dose methylprednisolone is an effective salvage treatment for heavily pretreated, unfit or refractory patients with chronic lymphocytic leukemia: single institution experience. ASH Annual Meeting Abstracts 2010;116:4638
66. Teichman ML, Ho VQ, Balducci L, et al. Efficacy of ofatumumab and high-dose methylprednisolone for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL). ASH Annual Meeting Abstracts 2011;118:4619
67. Spaner DE. Oral high-dose glucocorticoids and Ofatumumab in fludarabine-resistant chronic lymphocytic leukemia. Leukemia 2011: [Epub ahead of print]
68. Pettitt AR, Matutes E, Oscier D. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia 2006;201:441-5.
69. Stilgenbauer S, Cymbalista F, Leblond V, et al. Alemtuzumab plus oral dexamethasone, followed by alemtuzumab maintenance or allogeneic transplantation in ultra high-risk CLL: interim Analysis of a Phase II Study of the GCLLSG and fcgcll/MW. ASH Annual Meeting Abstracts 2011;118:2854